Our overall goal is a compreiiensive molecular genetic and functional analysis of two of the most common soft tissue sarcomas, myxofibrosarcoma (MYXF) and pleomorphic malignant fibrous histiocytoma (PMFH), so as to elucidate the mutational programs and pathways involved in sarcomagenesis and to identify novel therapeutic targets. Tissue samples and cell lines of MYXF and PMFH will be subjected to a multiplatform genome-wide characterization of expression of protein-coding genes and microRNAs, DNA copy number changes, activating mutations, and gene rearrangements. These data will be used to identify both genetically distinct subtypes of MYXF and PMFH and molecular signatures associated with tumor morphology, grade, recurrence, and survival. To identify potential therapeutic targets, we will screen the genes and microRNAs in these signatures for involvement in proliferation, differentiation, and survival of MYXF and PMFH cell lines. Potential targets will be validated by functional assays in additional cell lines and in xenografts. To achieve these goals, we have assembled a multidisciplinary group of investigators armed with 2 unique resources: a database of prospectively collected clinical-pathologic and outcomes data on over 8300 patients treated for soft tissue sarcoma at MSKCC, and a linl

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-02
Application #
8314124
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
2
Fiscal Year
2011
Total Cost
$268,810
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Katabi, Nora; Xu, Bin; Jungbluth, Achim A et al. (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72:285-293
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Flucke, Uta; Eijkelenboom, Astrid et al. (2018) Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms. Am J Surg Pathol 42:522-528
Bartenstein, Diana W; Coe, Taylor M; Gordon, Samantha C et al. (2018) Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep 4:185-188
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
Owosho, Adepitan A; Estilo, Cherry L; Huryn, Joseph M et al. (2018) A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head Neck Pathol 12:151-159

Showing the most recent 10 out of 169 publications